Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) Short Interest Update

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 1,465,993 shares, a growth of 8,397.5% from the March 31st total of 17,252 shares. Currently, 4.3% of the company’s stock are short sold. Based on an average daily trading volume, of 365,632 shares, the days-to-cover ratio is presently 4.0 days.

Hedge Funds Weigh In On Drugs Made In America Acquisition

Large investors have recently bought and sold shares of the business. Quarry LP purchased a new position in Drugs Made In America Acquisition in the third quarter valued at $161,000. Sandia Investment Management LP purchased a new position in shares of Drugs Made In America Acquisition during the third quarter worth about $161,000. Lineage Point Capital LP purchased a new position in shares of Drugs Made In America Acquisition during the fourth quarter worth about $330,000. JPMorgan Chase & Co. purchased a new position in shares of Drugs Made In America Acquisition during the third quarter worth about $1,024,000. Finally, Shaolin Capital Management LLC purchased a new position in shares of Drugs Made In America Acquisition during the second quarter worth about $1,020,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Drugs Made In America Acquisition Price Performance

NASDAQ:DMAA opened at $10.55 on Friday. The business’s fifty day moving average price is $10.49 and its 200 day moving average price is $10.41. Drugs Made In America Acquisition has a 12 month low of $10.05 and a 12 month high of $10.56.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.